NCT03209206 is a Phase 2 clinical trial of Docetaxel in Urothelial Carcinoma, sponsored by Seoul National University Hospital.

Who is sponsoring NCT03209206?

NCT03209206 is sponsored by Seoul National University Hospital.

What drugs are being tested in NCT03209206?

Interventions in NCT03209206: Docetaxel, Placebo Normal saline.

What condition does NCT03209206 study?

NCT03209206 studies Urothelial Carcinoma.

Is NCT03209206 still recruiting?

NCT03209206 is currently status unknown. Last updated 22 December 2017.

Last reviewed 2017-12-22 · How we verify

NCT03209206

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence

Status unknown Phase 2 Last updated 22 December 2017

What this trial tests

Phase 2 trial testing Docetaxel in Urothelial Carcinoma in 84 participants. Status unknown.

Timeline

28 June 2017

Primary endpoint
19 June 2020

1 April 2022

Quick facts

Lead sponsor	Seoul National University Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	84
Start date	28 June 2017
Primary completion	19 June 2020
Estimated completion	1 April 2022
Sites	1 location across South Korea

Drugs / interventions tested

Docetaxel (Docetaxel) — full drug profile →
Placebo Normal saline

Conditions studied

Urothelial Carcinoma — all drugs for Urothelial Carcinoma →

Sponsor

Seoul National University Hospital

Who can join

Adults 19 to 85, any sex, with Urothelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators evaluated the efficacy of a single early intravesical instillation of doxetaxel in the prevention of bladder recurrence after nephroureterectomy or distal ureterectomy for upper urinary tract urothelial carcinoma (UUT-UC).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma.
Hwang EC, Sathianathen NJ, Jung JH, Kim MH, et al · · 2019 · cited 29× · PMID 31102534 · DOI 10.1002/14651858.cd013160.pub2
Intravesical Therapy for Upper Urinary Tract Urothelial Carcinoma: A Comprehensive Review.
Wang Z, Shi H, Xu Y, Fang Y, et al · · 2023 · cited 3× · PMID 37894387 · DOI 10.3390/cancers15205020

Verify or expand the search:

Other trials of Docetaxel

Trials testing the same drug.

NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
NCT07361484 — Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy a · Phase 3 · not yet recruiting
NCT07415031 — A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting
NCT07487896 — A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esopha · Phase 3 · not yet recruiting

Other recruiting trials for Urothelial Carcinoma

Currently open trials in the same condition.

NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
NCT07421700 — Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer · Phase 1, PHASE2 · recruiting
NCT07492628 — Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma · Phase 1 · recruiting
NCT07390617 — A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma · recruiting

Other Seoul National University Hospital trials

Trials by the same sponsor.

NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03209206 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
Last refreshed: 22 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03209206.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing